HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

R333

a JAK3 inhibitor;

Also Known As:

JAK Inhibitor R333; Janus Kinase Inhibitor R333; R333 compound

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Oxazoles: 89
      - R333: 2

Experts

1.	Li, Jing: 1 article (12/2020)
2.	Li, Mengtao: 1 article (12/2020)
3.	Tian, Xinping: 1 article (12/2020)
4.	Wang, Qian: 1 article (12/2020)
5.	Xu, Dong: 1 article (12/2020)
6.	You, Hanxiao: 1 article (12/2020)
7.	Zeng, Xiaofeng: 1 article (12/2020)
8.	Zhao, Jiuliang: 1 article (12/2020)
9.	Feng, R: 1 article (01/2018)
10.	Fiorentino, D: 1 article (01/2018)

Related Diseases

1.	Vasculitis (Vasculitides) 12/01/2020 - "We also discuss the efficacy of the first- and second-generation JAK inhibitors (tofacitinib, baricitinib, ruxolitinib, peficitinib, filgotinib, upadacitinib, solcitinib, itacitinib, decernotinib, R333, and pf-06651600) for CTDs including RA, systemic lupus erythematosus, dermatomyositis, systemic sclerosis, Sjögren's syndrome, and vasculitis, based on laboratory and clinical research findings. "
2.	Systemic Scleroderma (Systemic Sclerosis) 12/01/2020 - "We also discuss the efficacy of the first- and second-generation JAK inhibitors (tofacitinib, baricitinib, ruxolitinib, peficitinib, filgotinib, upadacitinib, solcitinib, itacitinib, decernotinib, R333, and pf-06651600) for CTDs including RA, systemic lupus erythematosus, dermatomyositis, systemic sclerosis, Sjögren's syndrome, and vasculitis, based on laboratory and clinical research findings. "
3.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 12/01/2020 - "We also discuss the efficacy of the first- and second-generation JAK inhibitors (tofacitinib, baricitinib, ruxolitinib, peficitinib, filgotinib, upadacitinib, solcitinib, itacitinib, decernotinib, R333, and pf-06651600) for CTDs including RA, systemic lupus erythematosus, dermatomyositis, systemic sclerosis, Sjögren's syndrome, and vasculitis, based on laboratory and clinical research findings. "
4.	Dermatomyositis (Dermatopolymyositis) 12/01/2020 - "We also discuss the efficacy of the first- and second-generation JAK inhibitors (tofacitinib, baricitinib, ruxolitinib, peficitinib, filgotinib, upadacitinib, solcitinib, itacitinib, decernotinib, R333, and pf-06651600) for CTDs including RA, systemic lupus erythematosus, dermatomyositis, systemic sclerosis, Sjögren's syndrome, and vasculitis, based on laboratory and clinical research findings. "
5.	Discoid Lupus Erythematosus 01/01/2018 - "Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus." 01/01/2018 - "R333 is a topical janus kinase and spleen tyrosine kinase inhibitor being evaluated for discoid lupus erythematosus (DLE) treatment. "

Related Drugs and Biologics

1.	Janus Kinase Inhibitors
2.	GLPG0634
3.	ruxolitinib
4.	tofacitinib
5.	beta-cyclodextrin tetradecasulfate (CTDS)
6.	itacitinib
7.	upadacitinib
8.	peficitinib
9.	2- ((2- (1H- pyrrolo(2,3- b)pyridin- 3- yl)pyrimidin- 4- yl)amino)- 2- methyl- N- (2,2,2- trifluoroethyl)butanamide
10.	baricitinib